Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report
Lithium has shown the capacity to: a) inhibit the replication of several types of viruses, some of which are similar to the SARS-CoV-2 virus, b) increase the immune response by reducing lymphopenia, and c) reduce inflammation by preventing or reducing the cytokine storm. In the present study, we hav...
Main Authors: | Carlos Spuch, Marta López-García, Tania Rivera-Baltanás, Daniela Rodrígues-Amorím, José M. Olivares |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.557629/full |
Similar Items
-
A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine
by: Daniela Rodrigues-Amorim, et al.
Published: (2020-10-01) -
Lithium-induced nephropathy; One medication with multiple side effects: a case report
by: Pingchuan Zhang, et al.
Published: (2022-09-01) -
Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients
by: Carlos Spuch, et al.
Published: (2022-04-01) -
Chronic Lithium Toxicity in Old Age Patients Taking Angiotensin Receptor Blocker: A Case Report
by: Asim Pandey, et al.
Published: (2023-11-01) -
Electroconvulsive therapy combined with lithium developed reversible pure anomic aphasia: a case report
by: Qian Yang, et al.
Published: (2022-10-01)